Skip to main content
. 2020 May 11;2020(5):CD003689. doi: 10.1002/14651858.CD003689.pub4

Comparison 3. Pharmacological interventions (psychostimulants) versus placebo.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
3.1 Depression: average change in scores between baseline and end of treatment 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1.1 HDRS (high score = more depressed) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1.2 ZDS (high score = more depressed) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.2 Cognition: average change in scores between baseline and end of treatment 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.2.1 MMSE (low score = cognitive impairment) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.3 Disability: average change in scores between baseline and end of treatment 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.3.1 Fugl‐Meyer Scale (high score = better function) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.3.2 Functional Independence Measure (high score = independence) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.4 Adverse events: death 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
3.4.1 At end of treatment 1 21 Risk Ratio (M‐H, Fixed, 95% CI) Not estimable
3.5 Adverse events: leaving the study early (including death) 1   Risk Ratio (M‐H, Fixed, 95% CI) Totals not selected
3.5.1 All dropouts and withdrawals 1   Risk Ratio (M‐H, Fixed, 95% CI) Totals not selected